Clinical Trial Update: Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating neoadjuvant CAPOX plus tislelizumab vs CAPOX alone in MSS high-risk locally advanced colon cancer. The study status is NOT_YET_REC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: First Affiliated Hospital of Guangxi Medical University | Conditions: Colonic Neoplasms, Neoadjuvant Therapy | Phase 3 | Status: NOT_YET_RECRUITING